1-(866)-668-9038 (TOLL FREE)
3511 46th Avenue NE
Seattle, Washington 98105
This website reports
on Screen's set of self-administered cognition tests, the CANS-MCI, designed
to screen for Mild Cognitive Impairment* in geriatric care offices. Such
screening offers the most economical yet valid predictive information
about the need to professionally evaluate older people for signs of Alzheimer's
disease. Unlike PET scans, Compound B, spinal taps, or genetic tests,
the CANS-MCI can be used very economically to detect the very beginning
of the disease process, not the propensity to eventually get the disease
or the extent of the disease once it is symptomatic. The tests within
the CANS-MCI are the most predictive of conversion to Alzheimer's. The
CANS-MCI was developed with research support from the VA and from the
National Institute on Aging, leading to journal publications. Validity
results were first published as an extended article in a 2005 issue of
the peer-reviewed Journal
of Neuropsychiatry and Clinical Neurosciences.
The accurate anticipation
of cognitive decline results in substantial reductions of costs, both
emotional and financial, to patients, families, doctors, and retirement
facilities. When better treatments emerge, a record of baseline abilities
will allow doctors to perform expensive evaluations for possible treatment
as soon as impairment begins, rather than waiting for more severe impairments
to be evident. This is crucial because new treatments are likely to slow
or stop, not reverse, cognitive decline.
A great deal of
clinical information concerning Mild Cognitive Impairment* is not gathered
by doctors in time to provide early decisions about diagnosis and/or treatment.
These tests are designed to enhance the acquisition of intervention-related
information in the doctor's office. The CANS-MCI was developed over a
six year period to be objective yet fully self-administered in settings
appropriate for testing, requiring a minimal amount of staff time or training.
Graphical, longitudinal analyses with recommendations for professional
neuropsychological evaluations are returned the same day (usually within
30 minutes) to doctors' offices where testing is performed.
Support Screening Tests For Mild Cognitive Impairments:
Screen, Inc. presented
its initial test validity
results at the 8th International Conference on Alzheimer's Disease
& Related Disorders in Stockholm, Sweden. Factor analysis results
were presented at the American Association of Geriatric
Psychiatry convention in March, 2003.
Validity results were first published as an extended article in a 2005
issue of the peer-reviewed Journal
of Neuropsychiatry and Clinical Neurosciences. The sensitivity
and specificity of the tests have been studied, using a full, independent
neuropsychological evaluation as the criterion standard. The CANS-MCI has been very favorably compared to other test batteries in an independent study of all computerized tests and has the highest rating for validity, reliability, normative data, excellent usability, and self-explanatory excellent interface.
If you wish to see
a multimedia presentation about the tests, their development, and supporting
research, you may download
an installer here.
* Mild Cognitive
Impairment (MCI) refers to the set of cognitive impairments that are most
predictive of Alzheimer's disease. It is beginning to also refer to the
subset of brain features that are characteristic of Alzheimer's but are
in between normal brains and those of Alzheimer's patients. MCI is sometimes
referred to as an early stage of Alzheimer's, sometimes as a precursor.
People with MCI are often, although not necessarily, in a transitional
phase between normal brain functioning and Alzheimer's. The Computer-Administered
Neuropsychological Screen for Mild Cognitive Impairment (the CANS-MCI)
detects changes in ability, even in high functioning people, that warrant
closer attention because they are the changes most predictive of further